Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:39:37 2024-04-29 pm EDT			5-day change	1st Jan Change
4.115 ^USD	-4.07%		-1.78%	-25.17%

Mar. 27	North American Morning Briefing : Stocks Edge -2-	DJ
Mar. 25	Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 04:04 pm EDT

Marker Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 0.762658 million compared to USD 0.790508 million a year ago. Net income was USD 2.52 million compared to net loss of USD 9.24 million a year ago. Basic loss per share from continuing operations was USD 0.47 compared to USD 0.63 a year ago. Diluted loss per share from continuing operations was USD 0.47 compared to USD 0.63 a year ago. Basic earnings per share was USD 0.29 compared to basic loss per share of USD 1.11 a year ago. Diluted earnings per share was USD 0.29 compared to diluted loss per share of USD 1.11 a year ago.
For the six months, revenue was USD 2 million compared to USD 1.75 million a year ago. Net loss was USD 2.45 million compared to USD 19.15 million a year ago. Basic loss per share from continuing operations was USD 0.95 compared to USD 1.32 a year ago. Diluted loss per share from continuing operations was USD 0.95 compared to USD 1.32 a year ago. Basic loss per share was USD 0.28 compared to USD 2.3 a year ago. Diluted loss per share was USD 0.28 compared to USD 2.3 a year ago.

Latest news about Marker Therapeutics, Inc.

North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601	Jan. 22	CI
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	Jan. 08	CI
Top Midday Gainers	Dec. 11	MT
Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study	Dec. 11	CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $257.6M	Nov. 09	MT
Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse	23-09-11	CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q2 Revenue $762,658	23-08-14	MT
Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Transcript : Marker Therapeutics, Inc. - Special Call	23-08-09
Marker Therapeutics Says Non-clinical Data Show MT-401 Inducing Anti-tumor Activity in Specific Setting	23-08-07	MT
Marker Therapeutics Says Acute Myeloid Leukemia Treatment Candidate Granted Orphan Drug Designation in European Union	23-07-10	MT
Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen-Specific T Cell Product Candidate, Mt-401	23-07-10	CI
Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer	23-07-03	CI
Correction: Marker Therapeutics Says MT-401 Non-clinical Data Show Anti-Tumor Activity Against Acute Myeloid Leukemia	23-06-26	MT
Marker Therapeutics Says MT-401 Non-clinical Data Show Anti-Tumor Activity Against Acute Myeloid Leukemia	23-06-26	MT
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration	23-06-26	CI
Cell Ready, LLC completed the acquisition of Certain Cell Manufacturing Assets of Marker Therapeutics, Inc.	23-06-25	CI
Marker Therapeutics Says First Patient Dosed in Phase 1 Trial of Lymphoma Treatment	23-06-12	MT
Sector Update: Health Care Stocks Advancing Late Wednesday	23-05-31	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-05-31	MT
Top Midday Gainers	23-05-31	MT

Chart Marker Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
MARKER THERAPEUTICS, INC.	-25.17%	38.24M
IQVIA HOLDINGS INC.	+2.17%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.21%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+6.43%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-22.92%	18.12B
MEDPACE HOLDINGS, INC.	+30.28%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.10%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.99%	11B

Other Biotechnology & Medical Research